Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REINFORCE: Docetaxel Intensification After Suboptimal PSA Response to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer
2025-524408-30-01Phase 3Authorised
- Sponsor
- GUARD Consortium
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of lutetium Lu 177 PSMA I&T and apalutamide in prostate cancer (PCa) (2 arms), sponsored by GUARD Consortium. Primary endpoint: Event-free survival. Planned start Jun 2026; status: authorised.
02
Drugs
lutetium Lu 177 PSMA I&Tapalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2025-524408-30-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524408-30-01.